The DLBCL90 Gene-expression Assay Identifies Double-hit Lymphomas with High Sensitivity in Patients from Two Phase II Clinical Trials with High-risk Diffuse Large B-cell Lymphoma

Overview

Journal EJHaem

Specialty Hematology

Date 2022 Jul 18

PMID 35846101

Authors

Kathrine T Isaksen

Klaus Beiske

Erlend B Smeland

Judit Jorgensen

Marianne Brodtkorb

June Helen Myklebust

Mats Jerkeman

Leo Meriranta

Marja-Liisa Karjalainen-Lindsberg

Sirpa Leppa

David W Scott

Harald Holte

Yngvild Nuvin Blaker

Affiliations

Soon will be listed here.

Citing Articles

The DLBCL90 gene-expression assay identifies double-hit lymphomas with high sensitivity in patients from two phase II clinical trials with high-risk diffuse large B-cell lymphoma.

Isaksen K, Beiske K, Smeland E, Jorgensen J, Brodtkorb M, Myklebust J EJHaem. 2022; 2(1):104-108.

PMID: 35846101 PMC: 9175840. DOI: 10.1002/jha2.109.

The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.

Hwang J, Suh C, Kim K, Kim H, Kim A, Craig J Cancers (Basel). 2021; 13(13).

PMID: 34282799 PMC: 8268769. DOI: 10.3390/cancers13133369.

References

Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E . Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood. 2018; 132(22):2401-2405. PMC: 6265647. DOI: 10.1182/blood-2018-05-851154. View

Schmitz R, Wright G, Huang D, Johnson C, Phelan J, Wang J . Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 378(15):1396-1407. PMC: 6010183. DOI: 10.1056/NEJMoa1801445. View

Petrich A, Gandhi M, Jovanovic B, Castillo J, Rajguru S, Yang D . Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014; 124(15):2354-61. DOI: 10.1182/blood-2014-05-578963. View

Holte H, Leppa S, Bjorkholm M, Fluge O, Jyrkkio S, Delabie J . Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2012; 24(5):1385-92. DOI: 10.1093/annonc/mds621. View

Scott D, King R, Staiger A, Ben-Neriah S, Jiang A, Horn H . High-grade B-cell lymphoma with and and/or rearrangements with diffuse large B-cell lymphoma morphology. Blood. 2018; 131(18):2060-2064. PMC: 6158813. DOI: 10.1182/blood-2017-12-820605. View

Leppa S, Jorgensen J, Tierens A, Meriranta L, Ostlie I, de Nully Brown P . Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Adv. 2020; 4(9):1906-1915. PMC: 7218416. DOI: 10.1182/bloodadvances.2020001518. View

Hilton L, Tang J, Ben-Neriah S, Alcaide M, Jiang A, Grande B . The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH. Blood. 2019; 134(18):1528-1532. PMC: 6839951. DOI: 10.1182/blood.2019002600. View

Ennishi D, Jiang A, Boyle M, Collinge B, Grande B, Ben-Neriah S . Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2018; 37(3):190-201. PMC: 6804880. DOI: 10.1200/JCO.18.01583. View

Isaksen K, Beiske K, Smeland E, Jorgensen J, Brodtkorb M, Myklebust J . The DLBCL90 gene-expression assay identifies double-hit lymphomas with high sensitivity in patients from two phase II clinical trials with high-risk diffuse large B-cell lymphoma. EJHaem. 2022; 2(1):104-108. PMC: 9175840. DOI: 10.1002/jha2.109. View

10.

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

11.

Sha C, Barrans S, Cucco F, Bentley M, Care M, Cummin T . Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy. J Clin Oncol. 2018; 37(3):202-212. PMC: 6338391. DOI: 10.1200/JCO.18.01314. View

12.

Scott D, Wright G, Williams P, Lih C, Walsh W, Jaffe E . Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014; 123(8):1214-7. PMC: 3931191. DOI: 10.1182/blood-2013-11-536433. View

13.

Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn M . Prognostic Significance of Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2019; 37(35):3359-3368. DOI: 10.1200/JCO.19.00743. View

14.

Scott D, Mottok A, Ennishi D, Wright G, Farinha P, Ben-Neriah S . Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. J Clin Oncol. 2015; 33(26):2848-56. PMC: 4554747. DOI: 10.1200/JCO.2014.60.2383. View

15.

Friedberg J . How I treat double-hit lymphoma. Blood. 2017; 130(5):590-596. DOI: 10.1182/blood-2017-04-737320. View